BRCA1 and ovarian carcinoma: Olaparib has demonstrated single agent activity in breast or ovarian cancer patients with germline mutations in BRCA1/2 [20-22]; an over 40% response rate has been reported in patients with BRCA mutant ovarian cancer, especially in patients with platinum sensitive disease [23].